Phase II study of OSI-774 in patients with metastatic colorectal cancer

被引：0

作者：

Townsley, C

Major, P

Siu, LL

Dancey, J

Vincent, M

Pond, G

MacLean, M

Moore, MJ

Oza, AM

机构：

[1] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada

[2] Hamilton Reg Canc Ctr, Dept Med Oncol, Hamilton, ON L8V 1C3, Canada

[3] Natl Canc Inst, Div Canc Treatment Diagnosis Ctr, Rockville, MD USA

[4] London Reg Canc Ctr, Dept Med Oncol, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

179

引用

页码：S57 / S57

页数：1

共 50 条

[21] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
Hidalgo, M
Siu, LL
Nemunaitis, J
Rizzo, J
Hammond, LA
Takimoto, C
Eckhardt, SG
Tolcher, A
Britten, CD
Denis, L
Ferrante, K
Von Hoff, DD
Silberman, S
Rowinsky, EK
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3267 - 3279
[22] OSI-774 (Tarceva) in patients (pts) with unresectable or metastatic hepatocellular carcinoma (HCC): A multi-center phase 2 consortium (P2C) study.
Philip, PA
Mahoney, MR
Thomas, JP
Pitot, HC
Donehower, R
Kim, GP
Picus, J
Fitch, TR
Geyer, SM
Erlichman, C
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6096S - 6096S
[23] Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
Kraut, Eric H.
Rhoades, Christopher
Zhang, Yilong
Cheng, Hao
Aimiumu, Josephine
Chen, Ping
Lang, James
Young, Donn C.
Agrawal, Amit
Dancey, Janet
Chan, Kenneth K.
Grever, Michael R.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 579 - 586
[24] A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer
Pelley, R
Ganapathi, R
Wood, L
Rybicki, L
McLain, D
Budd, GT
Peereboom, D
Olencki, T
Bukowski, RM
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (03) : 251 - 254
[25] A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer
Robert Pelley
Ram Ganapathi
Laura Wood
Lisa Rybicki
Denise McLain
G. Thomas Budd
David Peereboom
Thomas Olencki
Ronald M. Bukowski
G. Thomas Budd
Cancer Chemotherapy and Pharmacology, 2000, 46 : 251 - 254
[26] Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
Eric H. Kraut
Christopher Rhoades
Yilong Zhang
Hao Cheng
Josephine Aimiumu
Ping Chen
James Lang
Donn C. Young
Amit Agrawal
Janet Dancey
Kenneth K. Chan
Michael R. Grever
Cancer Chemotherapy and Pharmacology, 2011, 67 : 579 - 586
[27] Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
Hesketh, Paul J.
Chansky, Kari
Wozniak, Antoinette J.
Hirsch, Fred R.
Spreafico, Anna
Moon, James.
Mack, Philip C.
Marchello, Benjamin T.
Franklin, Wilbur A.
Crowley, John J.
Gandara, David R.
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1026 - 1031
[28] Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer
Lissandra Dal Lago
Marc F. Richter
Anna I. Cancela
Sabrina A. Fernandes
Keylla T. Jung
Ana C. Rodrigues
Teresa Dalla Costa
Luciane P. Di Leone
Gilberto Schwartsmann
Investigational New Drugs, 2003, 21 : 359 - 366
[29] Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer
Dal Lago, L
Richter, MF
Cancela, AI
Fernandes, SA
Jung, KT
Rodrigues, AC
Dalla Costa, T
Di Leone, LP
Schwartsmann, G
INVESTIGATIONAL NEW DRUGS, 2003, 21 (03) : 359 - 366
[30] Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC)
Iqbal, S.
Yang, D.
Cole, S.
El-Khoueiry, A. B.
Boswell, W.
Agafitei, R.
Lujan, R.
Lenz, H. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →